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Abstract
Verotoxigenic Escherichia coli (VTEC) are a specialized
group of E. coli that can cause severe colonic disease
and renal failure. Their pathogenicity derives from
virulence factors that enable the bacteria to colonize
the colon and deliver extremely powerful toxins
known as verotoxins (VT) or Shiga toxins (Stx) to the
systemic circulation. The recent devastating E. coli
O104:H4 epidemic in Europe has shown how helpless
medical professionals are in terms of offering effective
therapies. By examining the sources and distribution
of these bacteria, and how they cause disease, we will
be in a better position to prevent and treat the
inevitable future cases of sporadic disease and victims
of common source outbreaks. Due to the complexity
of pathogenesis, it is likely a multitargeted approach
is warranted. Developments in terms of these
treatments are discussed.
See related article: http://www.biomedcentral.com/
1741-7015/10/11
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Introduction
The association of verotoxigenic Escherichia coli (VTEC)
with human disease goes back over 30 years [1-3]. The
occurrence of outbreaks due to VTEC in the USA in
1982 [4] focused the world’s attention onto these patho-
gens. Since the discovery of verocytotoxin [1,3], and the
paper by Karmali et al. [5] of cases of post-diarrheal
hemolytic uremic syndrome (D+HUS) caused by VTEC,
otherwise known as Shiga-toxigenic Escherichia coli
(STEC), a large body of knowledge has accumulated, yet
despite this information, successful treatment of these
infections has remained elusive.
Sources and pathogenesis of VTEC infection
Sources and spread of VTEC
Gut colonization of farm animals, especially ruminants
such as cattle, sheep and goats is the likely origin of
VTEC/STEC. From these sources derive a variety of vehi-
cles of transmission to humans, including many different
foods of animal or plant origin, and water used for swim-
ming and drinking and for growing edible plants. Human
fecal contamination of food and seeds could also play a
role, especially in developing countries [6].
The potential for VTEC spread is further compounded
by globalization of food, which presents a great opportu-
nity for VTEC to spread quickly to large sections of the
population. Global food distribution carries an inherent
risk and presents great difficulties in controlling food-
borne pathogens and in identifying sources of outbreaks,
as was recently witnessed in Europe. This is further dis-
cussed in the commentary by Werber et al. [7].
VTEC strains
Various strains of VTEC exist, and, as discussed in the
linked commentary, O157 clones, although less preva-
lent than non-O157 strains, tend to be more virulent.
Thus, although non-O157 VTEC strains had originally
been reported and continued to be reported, albeit only
by dedicated microbiologists, most researchers in the
field largely ignored them. No attention appears to have
been given to the generally observed fact that there is a
widespread diversity of E. coli serotypes in the human
intestine at any one time [8] and this has also been
found in animals, especially cattle [9]. Most ruminant
feces contain a variety of VTEC serotypes, but some,
such as O157 and also O111, though rarely present and
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Importantly, an increasing number of other serotypes
can be involved and one study of an outbreak has
shown that the more VTEC serotypes with which a
patient is infected, the worse the clinical condition [10]
(though the main VTEC serotype was O111). While iso-
lations of VTEC O111 from cattle are rare, non-VTEC
strains, which are otherwise indistinguishable from the
VTEC strains, appear abundant, especially in the feces
of sick cattle and patients [11].
Detailed studies [12] have shown that the Shiga toxins
can be subdivided into a series of subtypes and that
these are also host specific. Thus there is a ‘double host
specificity’ among VTEC strains. Some clones are speci-
fic to cattle, while others are specific to sheep. The
toxin subtypes these strains carry are specific to
the VTEC types found in these mammalian hosts.
Therefore, by not looking for the presence of all VTEC
serotypes during an outbreak, a great deal of epidemio-
logical information is lost and indication of the source
animal is not identified.
Pathogenesis of post-diarrheal hemolytic uremic syndrome
VTEC/STEC/enterohemorrhagic E. coli (EHEC) belong
to clones of zoonotic E. coli of different O serogroups.
These serogroups have evolved and acquired specific
virulence factors that enable the bacteria to colonize
and infect the human colon, usually without invasion of
t h eb l o o ds t r e a m[ 1 3 ] .O n c et h e yh a v eb e e ni n g e s t e d ,
STEC/VTEC/EHEC cause bloody diarrhea (BD), severe
colitis and HUS. These bacteria are known as EHEC
when infection is associated with severe colonic and/or
renal disease. The production of Vero/Shiga toxins have
been considered the basis for their pathogenicity, how-
ever, other toxins such as subtilase cytotoxin (SubAB)
[14] and cytolethal distending toxin [15] and secreted
protease of C1 esterase inh i b i t o rf r o mE H E C( S t c E )
probably play a role [16].
The recent outbreak of foodborne E. coli O104:H4 in
Europe has once again drawn attention to STEC or
EHEC infections together with their devastating compli-
cations of renal failure (through HUS), and stroke from
intravascular coagulopathy and vasculopathy or throm-
botic microangiopathy. The unusual virulence and leth-
ality of the O104:H4 strain is the result of genetic
admixture of virulence factors, including enteroaggrega-
tive properties and multiple antibiotic resistance, and is
a lesson in microbial evolution and the genomic plasti-
city of E. coli [17]. The O104:H4 strain is now known as
an enteroaggregative and enterohemorrhagic E. coli
(EAHEC).
We have recently observed the combined properties of
enteroaggregative ability (providing strong attachment
via fimbriae and colonization of the colonic epithelium)
with Shiga toxin (Stx) production in the novel and
highly lethal European E. coli O104:H4 strain. It has
since been shown that this strain belonged to an enter-
oaggregative E. coli lineage that had acquired genes for
Shiga toxin 2 and antibiotic resistance [18].
The pathogenesis of HUS disease remains incomple-
tely understood; remarkably, during HUS serum Stx is
undetectable. It seems polymorphonuclear leukocytes
(PMN) are key players in delivering Stx to critical sites
such as the kidneys. The extent of renal damage in chil-
dren with STEC-associated HUS may relate to the con-
centration of Stx present on circulating PMN [19].
Paradoxically, patients with high amounts of Stx on
PMN showed preserved or slightly impaired renal func-
tion (incomplete form of HUS), whereas cases with low
amounts of PMN-Stx usually present with acute renal
failure. Moreover, high amounts of PMN-Stx induce a
reduced release of cytokines by the renal endothelium,
with congruent lower degree of inflammation, while low
toxin PMN amounts trigger a cytokine cascade, provok-
ing inflammation with consequent tissue damage. The
microvasculature plays an important role in pathogen-
esis: D+HUS is associated with platelet thrombi in the
microvasculature of almost all vascular beds [20].
Plasma from HUS patients induces apoptosis of cultured
microvascular endothelial cells from most organs [21].
Two key events are involved in the pathogenesis of D
+HUS: altered Von Willebrand factor (VWF) activity
(for example, as seen with ‘a disintegrin and metallopro-
teinase with thrombospondin motif-13’ (ADAMTS13)
deficiency) and site-specific activation and/or apoptosis
of microvascular endothelial cells. A deficiency in
ADAMTS13, which mediates proteolytic processing of
newly released proadhesive ultralarge VWF multimers
from endothelial cells, is also thought to play a role in
D+HUS coagulopathy [22]. Targeting the interruption of
these processes gives hope for potential novel treatment
modalities.
Bacterial gut pathogens target the follicle-associated
epithelium overlying Peyer’s patches. The microorgan-
isms breech the intestinal barrier via M cells and are
captured by mucosal macrophages [23]. STEC/EHEC
are able to interact in vivo with Peyer’s patches and
translocate through the mucosa. After being taken up by
macrophages and M cells the bacteria produce Stx and
induce apoptosis of these host cells and Stx release.
These microbe/host cell interactions could represent
new therapeutic targets [23].
Current treatment strategies: a multitargeted approach
HUS comprises acute renal failure and its consequential
perturbation of fluid and electrolyte balance, hemolysis,
disruption of the clotting cascade with thrombocytope-
nia, with the risk of stroke. This syndrome, together
with the further effects of toxin, and complement com-
plex formation, must be managed and addressed
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the institution of general supportive measures, antiplate-
let and thrombolytic agents and thrombin inhibitors,
selective use of antimicrobials, probiotics, toxin neutrali-
zers (synthetic and natural binders, antibodies, and so
on); and antibodies against key pathogenetic pathway
elements to interrupt pathological processes (for
example, inhibition of terminal complement complex
formation). Targeting PMNs carrying Stx could be a
productive strategy for future research, as could possible
gene therapy. The management of D+HUS is complex
by virtue of the nature of the condition and the variety
of pathways affected. Table 1 summarizes the approach
to management and lists trialed and experimental
treatments.
General supportive measures
Fluid levels and electrolyte balance are extremely impor-
tant in preventing and managing the development of
HUS [24,25] (See Table 1).
Acute renal replacement therapy (ARRT); for example,
peritoneal dialysis (PD) or hemodialysis) has been
shown to improve outcomes. Children with D+HUS and
acute kidney injury given early PD may have improved
outcomes without risk of bleeding in patients with low
platelet counts. Moreover, the procedure seems safe
especially in cases with very low platelet counts with no
bleeding episodes recorded [26]. Alternatively, hemodia-
lysis is often necessary. Antihypertensive therapy for
hypertension when appropriate is also necessary. There
seems to be a beneficial role for plasma infusion [27]
and plasma exchange [28], however, benefit from apher-
esis remains uncertain [29].
Managing hematological issues and coagulopathy
Monitoring of hemoglobin, hematocrit and platelet
count is essential. Monitoring hemolysis with lactate
dehydrogenase (LDH) and haptoglobin is also helpful.
Anemia resulting from hemolysis may need correction
with transfusions of whole blood or packed red cells.
Platelet transfusion is rarely required and usually
avoided [13,30].
Preventing the further effects of toxin
Antimicrobials: to use or to avoid?
Due to the potential for undesirable release of verotoxin
(VT)/Stx by dying and dead bacterial cells, antibiotics
are usually avoided [31]. In addition, the risk of endo-
toxin release could add to the patient’s already poten-
tially lethal burden. In vitro subinhibitory concentrations
of antibiotics may increase production and release of
VT/Stx [32] via bacteriophage induction [33]. A mouse
[34] and piglet study [35] suggested human trials of fos-
fomycin were warranted. However, pooled prospective
data showed no benefit of antibiotics [36]. Only one
fosfomycin trial has been reported [37]. However,
fosfomycin data has been questioned [38] (See Table 1).
While many doctors in Japan still use antibiotics includ-
ing fosfomycin in patients with definite or possible
enteric STEC infections the prevailing consensus else-
where indicates antibiotics should be avoided [13]. More
recent evidence supports this especially in relation to b
lactam and other bactericidal antibiotics [39].
Lumenal toxin neutralizers (synthetic and natural binders,
antibodies, and so on)
Strategies using ligand mimics of the receptor for Stx,
globotriaosylceramide (Gb3), binding to Stx in the gas-
trointestinal tract with the intention of preventing the
spread of toxin to extraintestinal sites have been pro-
posed. However, in clinical practice the damage has
already been done before these ligands could be of ben-
efit. Only one clinical trial has been conducted (alas
unsuccessfully) with one agent, Synsorb PK, which bore
out this fact [40]. Other agents are listed in Table 1
[41,42].
Intralumenal neutralizers might be effective in redu-
cing systemic uptake of toxin but because the toxin is
purportedly not found in serum, studies designed to
examine the effect of neutralizers on the toxic effects of
polymorphonuclear leukocyte-associated toxin would be
a first step.
Antibodies
Neutralizing Shiga toxin-specific antibodies are poten-
tially useful as therapeutic agents. The toxins are AB
toxins with active and binding elements and are obvious
targets for antibody neutralization. Monoclonal antibo-
dies targeting the A subunit epitopes of Stx1 have been
s h o w nt ob eh i g h l yp r o t e c t ive, when administered to
lethally treated animals [43]. Orally administered immu-
noglobulin has been used therapeutically for a number
of gastrointestinal infections (for example, rotavirus;
Gastrogard-R) [44]. Patients with diarrhea caused by
diarrheagenic E. coli,s p e c i f i c a l l yS T E Ca n dE. coli-
expressing intimin and HEC-hemolysin were treated by
administration of pooled bovine colostrum, rich in anti-
bodies to Shiga toxin and enterohemorrhagic E. coli-
hemolysin, in a placebo-controlled, double-blind study.
Symptom resolution and fecal excretion of infecting
strains were assessed. No effect of colostrum therapy on
the carriage of the pathogens or on complications of the
infection could be demonstrated, however, stool fre-
quency was reduced [45]. Antibody to E. coli lipopoly-
saccharide (LPS) also has the potential of therapeutic
use through its blocking effect on adherence of STEC to
the human intestinal epithelial (Henle 407) cell line [46].
Likewise, human trials would be needed to show clinical
effectiveness.
Other toxin binders/neutralizers
Most of these agents bind to toxin directly and inhibit
the binding to its receptor present on the target cells
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Problem Treatment Detail and comments refs
Fluid and electrolyte
imbalance
Intravenous fluids Fluid balance and attention to the volume and sodium content of
intravenous fluids administered early in the disease have been shown to
reduce the risk of developing oligoanuric HUS after Escherichia coli O157:H7
infections
[25]
Intravenous fluids within first 4 days of onset of diarrhea (isotonic
preferable).
The overall oligoanuric rate of the 50 participants was 68%, but was 84%
among those not given intravenous fluids in the first 4 days of illness. The
relative risk of oligoanuria when fluids were not given in this interval was
1.6 (95% CI, 1.1 to 2.4; P = 0.02). Children with oligoanuric HUS were given
less total intravenous fluid (r = -0.32; P = 0.02) and sodium (r = -0.27; P =
0.05) in the first 4 days of illness than those without oligoanuria.
[24]
Acute renal failure Acute renal replacement therapy Peritoneal dialysis (safe with thrombocytopenia) Hemodialysis
Plasma infusion and plasma exchange
[26]
[27]
[28]
Apheresis Uncertain benefit [29]
Antihypertensives Where indicated [13,30]
Hematological:
hemolytic anemia
Transfusion (packed red cells) [13]
Hematological:
thrombocytopenia
Platelet transfusion (usually avoided) [13,30]
Preventing further
effects of toxin
Antibiotics Generally to be avoided because of VT/Stx/endotoxin release from dying/
dead bacteria. b-lactams to be avoided.
Subinhibitory levels may increase toxin production/release
[13]
[39]
[32]
The quinolone ciprofloxacin but not fosfomycin causes Shiga toxin-
encoding bacteriophage induction and enhanced Stx production from E.
coli O157:H7 in vitro and in vivo in a mouse model.
[33,34]
Fosfomycin showed evidence of better outcomes in a
mouse-model of STEC infection and was recommended for human studies.
Similar results were observed in a gnotobiotic piglet model. Pooled
prospective data showed no benefit of antibiotics There is only a single
study purportedly connecting fosfomycin with a reduced risk of HUS
[35]
Fosfomycin benefit in humans remains in doubt. The validity of the study
has been questioned on the basis that the meta-analysis mischaracterized
fosfomycin as being superior to no antibiotics.
[36]
Lumenal toxin neutralisers: Synthetic
ligand mimics
Synsorb K; trial showed no benefit [37]
Modified bacteria decorated with
Gb3 or Gb4 Super Twig (Gb3
polymer)
Not yet trialed
Clinical trials awaited
[40]
Antibodies: Monoclonal against A
subunit
Protective in lethally-challenged animals [41]
Oral bovine colostrum No effect on complications; decreases stool frequency but not STEC carriage [42]
LPS antibodies Reduces in vitro adherence. No human data. Experimental only. [43]
Receptor blockers and toxin
intracellular transport inhibitors
Ac-PPP-tet blocks intracellular transport of Stx2 from Golgi to endoplasmic
reticulum (essential for Stx2 toxicity)
Watanabe-Takahashi et al. reviewed other neutralizers that do not act on
receptor binding but disrupt intracellular transport of the toxin, effectively
neutralizing the toxin.
[45]
Systemic (intravenous) toxin binders [46]
[47]
Cell-permeable peptide binds to Stx2 and prevents acute kidney injury.
Increases survival in juvenile baboon model. TVP (5 mg/kg) delivered
intravenously and simultaneously with toxin or at 6 or 24 h after toxin with
daily 1 mg/kg supplements up to day 4 prevented acute kidney injury and
[47]
delayed and reduced blood urea and creatinine levels and increased
survival. Delayed administration of the peptide significantly reduced
thrombocytopenia, but had no effect on anemia. This cell-permeable agent
shows promise in counteracting Stx2 lethality in a baboon model; outcomes
of human trials are awaited.
[48]
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modality against STEC/EHEC infections [47] and are
detailed in Table 1.
Systemically-applied (intravenous) toxin binders
A cell-permeable peptide (TVP) that binds to Stx2 was
shown to reduce disease severity and rescue juvenile
baboons from a lethal Stx2 dose (50 ng/kg) [48].
Blockers of endosome-to-Golgi trafficking of Stx
Recently it was shown that the metal manganese (Mn
2+)
blocks endosome-to-Golgi trafficking of STx. [49] This
offers a possible cheap therapeutic approach. (Table 1).
Blockers of bacterial and host cell interaction: probiotics
Gut pathogens display surface molecules enabling the
organism to bind to host cell receptors. Similarly, bac-
terial toxins require host cell receptors for binding and
cell entry. To block microbe and host cell interaction
‘designer’ probiotics have been developed. The harmless
recombinant bacteria express molecules that mimic host
cell receptors (for example, Gb3) on their surface,
thereby deceiving the pathogen into attaching to the
probiotic rather than the host cell receptor. Probiotic
bacteria must survive the tube journey encountering
digestive enzymes and other adverse conditions. Trial
data is awaited.
A different approach has used the supernatant of cul-
tures of Bifidobacterium longum HY8001, designed to
inhibit the effect of VT/Stx through interference of B
subunit of VTs in binding to Gb3 [50].
Inhibition of terminal complement complex formation
Based on evidence that Shiga toxin activates comple-
ment and binds factor H and evidence for an active role
of complement via the alternative pathway in diarrhea-
Table 1 Approach to management: summarizing trialed and experimental treatments. (Continued)
Blockers of endosome-to-Golgi
trafficking of Stx
Recently it was shown that the metal manganese (Mn
2+) blocks endosome-
to-Golgi trafficking of STx and causes its degradation in lysosomes. Mn2+
targets the cycling Golgi protein GPP130. Direct trafficking of STx from early
endosomes to the Golgi, (bypassing late endosomes and lysosomes), is a
crucial step that allows STx to avoid degradation. Mn
2+, as a small-molecule
inhibitor targeting this step therefore offers a cheap therapeutic modality
given that mice injected with nontoxic doses of Mn2+ were completely
resistant to a lethal STx challenge.
[49]
[49]
Blockers of bacterial
and host cell
interaction
Probiotics Harmless recombinant bacteria expressing surface molecules that mimic
host cell receptors, deceiving pathogen into attaching to probiotic cell
rather than the host cell receptor. Unlikely to benefit symptomatic patients
but could be beneficial as prophylactic for family and close contact/exposed
persons. Supernatant of cultures of Bifidobacterium longum HY8001 is
designed to inhibit the effect of VT/Stx through interference of B subunit of
VTs in binding to Gb3.
[50]
Terminal complement
complex formation
Eculizumab (intravenous) This monoclonal antibody blocks activation of complement and Factor H
binding via alternative pathway.
[51,52]
Promising results in small clinical pilot study. The antibody was given
intravenously at 7 day intervals, twice in two patients and four times in a
third patient.
[53]
Immunoprophylaxis Vaccines Promising results in animal studies using:
(1) virulence proteins (Stx1/2, intimin, EspA;
peptides;
[54]
[55]
fusion proteins of A and B Stx subunits); [56]
(2) avirulent ghost cells of EHEC O157:H7; [57]
(3) live attenuated bacteria expressing
recombinant proteins. Gu et al. used a live attenuated EIS-producing
Salmonella vaccine in mice model. Vaccination induced significant increases
of EspA, intimin and Stx2 specific IgG in serum and secretory IgA in feces as
well as antigen-specific T cell proliferation;
[58]
(4) recombinant fimbrial proteins have been developed in a quest to
protect against the STEC-related entity piglet edema disease. Early results
are mixed.
[59]
Tir, EspB, EspD, NleA, and EspA were highly immunogenic in vaccinated and
naturally infected subjects and represent future candidates for a STEC
vaccine;
[60]
(5) DNA vaccines: EHEC Stx2 A2 and B subunits confer immunity in a mouse
model;
[61]
(6) plant-based oral recombinant Stx2 vaccine protects mice. [62]
EHEC = enterohemorrhagic Escherichia coli; EspA/B/D = E. coli secreted protein A/B/D; Gb3 = globotriaosylceramide; Gb4 = globotetraosylceramide; HUS =
hemolytic uremic syndrome; LPS = lipopolysaccharide; NleA = non-LEE-encoded effector A; STEC = Shiga-toxigenic Escherichia coli; Stx = Shiga toxin; Tir =
translocated intimin receptor; VT = verotoxin.
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anecdotal reports of successful treatment of severe Stx-
associated HUS with the monoclonal antibody eculizu-
mab have been published [53]. Neurologically, the three
patients improved dramatically within 24 h after the
first eculizumab infusion. Clinical improvement was
associated with rapid normalization of markers of dis-
ease activity. These initial results are extremely promis-
ing and outcomes from large-scale randomized placebo-
controlled trials are optimistically awaited.
Vaccines
Several vaccine strategies have been used with variable
success in a number of animal models. The strategies
have involved the use of recombinant virulence proteins
such as Stx, intimin and E. coli secreted protein A
(EspA) [54] or peptides [55] or fusion proteins of A and
B subunits of Stx2 and Stx1 such as Stx2Am-Stx1B [56]
or avirulent ghost cells of EHEC O157:H7 [57]. The
application of live attenuated bacteria such as Salmo-
nella as a carrier for vaccine proteins against mucosal
pathogens including EHEC have obvious advantages
[58]. Other approaches are listed in Table 1[59-62].
Antibodies produced in humans with HUS and in rab-
bits immunized with type III secreted proteins (T3SPs)
from four STEC serotypes, and experimentally infected
cattle revealed proteins common to several HUS sero-
types [60] (Table 1). These were highly immunogenic in
vaccinated and naturally infected subjects and represent
future candidates for a STEC vaccine (Table 1).
As well as protein-based vaccines, DNA vaccines are a
recent development in EHEC prevention, providing
encouraging results in a mouse model [61] (Table 1).
The mode of administration (intramuscular, intranasal,
oral, intragastric, and so on) for a number of these vac-
cines not only affects immunogenicity but also protec-
tive effect under challenge. Vaccination with a plant-
based oral vaccine protected mice against lethal systemic
intoxication with Stx2 [62]. This is seen as encouraging.
Clearly there is some time to go before human trials are
reported but the numerous and frequent outbreaks of
EHEC disease constantly remind us of the urgent need
to protect the population against these emerging and
often devastating zoonoses.
Future directions and conclusions
There remain significant barriers to successful treatment
of HUS given the complexity of the pathogenesis of
HUS, which involves perturbation of key homeostatic
pathways involving complex biochemical and physiologi-
cal systems. It is unlikely that targeting a single pathway
with a treatment modality will be sufficiently successful;
a multitargeted approach would seem necessary. How-
ever, given the apparent success of eculizumab, albeit
with tiny case numbers, it could offer a promising strat-
egy for treatment. Treatment is designed to prevent the
most serious complications of STEC infection (that is,
renal failure and central nervous complications, for
example, stroke, and shock), which remain far too com-
mon. It is clear that a better understanding of the
pathogenesis of HUS will lead to additional and possibly
better targets for treatment. The discovery that Mn
2+
can block endosome-to-Golgi trafficking will no doubt
lead to randomised controlled trials in humans. These
will be awaited with keen interest. In terms of preven-
tion, we should question the globalization of food distri-
bution with its inherent dangers and its wasteful use of
energy resources resulting in a giant carbon footprint.
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